AUSTRALIA
info@sudapharma.com
Facebook
Twitter
Linkedin
YouTube
+61 8 6142 5555
Menu
About Us
Snapshot
Our People
Leadership Team
Management Team
Scientific Advisory Board Members
Corporate Governance and Charters
Technology
Products
Zolpimist™ – Treatment for Insomnia
R&D
Anagrelide: Treatment for Cancer
Sumatriptan: Treatment for Migraine
Cannabinoids (CBD)
Ondansetron : Nausea
Sildenafil : Erectile Dysfunction/PAH
Midazolam: Treatment for Epilepsy & Anxiety
Investors
ASX Announcements
Presentations
Analyst Reports
Media
Contact Us
Annual Reports
30 June 2018
30 June 2017
30 June 2016
Recent Agreements
Latest SUDA Investor Presentation>>
ASX Announcements
26 Feb 21
Anagrelide Project Update
26 Feb 21
Appendix 4D & Interim Financial Half Year Report FY2021
16 Feb 21
Change of Director’s Interest Notice
16 Feb 21
Change of Director’s Interest Notice
16 Feb 21
Change of Director’s Interest Notice
